Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesDiseases and Disorders of the Skin, Subcutaneous Tissue and BreastDRG 575-skin-graft-for-skin-ulcer-or-cellulitis-without-cc-mcc
    Ask Trek AI about this page

    Skin Graft for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    DRG 575 encompasses inpatient stays for skin grafting related to skin ulcers or cellulitis when no Major Complication or Comorbidity or Complication or Comorbidity is present. This Diagnosis-Related Group defines the clinical scope for payment grouping and affects Medicare inpatient reimbursement by establishing the payment weight for these straightforward graft procedures.

    Customize your policy alerts

    Sign up for drg 575 policy alerts

    Get alerted when payer policies referencing 575 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 575 Overview

    DRG 575 covers inpatient admissions for patients receiving skin graft procedures for skin ulcers or cellulitis without a Major Complication or Comorbidity or a Complication or Comorbidity. It includes cases where the primary surgical intervention is grafting to promote wound closure in the setting of ulceration or soft tissue infection without additional documented higher-severity diagnoses. This Diagnosis-Related Group is used by Centers for Medicare & Medicaid Services for categorizing hospital stays and determining bundled Medicare inpatient reimbursement. Accurate clinical documentation and coding of the principal procedure and comorbid conditions influence assignment to this Diagnosis-Related Group and the corresponding payment.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Randomized controlled trials comparing alternative skin grafting techniques or biologic graft materials for lower extremity pressure ulcers and cellulitis-related soft tissue defects: these studies enroll hospitalized adults undergoing surgical debridement and immediate grafting to compare outcomes such as graft take rate, time to wound closure, intra‑hospital complication rates, and length of stay. They address an acute perioperative intervention and are directly relevant to surgeons, hospital care teams, and payers by informing choices that can reduce reoperation, shorten inpatient LOS, and lower complication‑related costs.
    • Comparative effectiveness studies of perioperative infection control and antibiotic stewardship strategies in patients with skin ulcers complicated by cellulitis: these observational or pragmatic trial designs evaluate different antibiotic duration strategies, timing of therapy relative to debridement/grafting, and adjunctive local antimicrobial dressings in adults with comorbidities (eg, diabetes, peripheral vascular disease). This research targets the high‑risk inpatient population typical of this DRG and is important for providers and payers because optimized protocols can reduce readmissions for surgical site infection and antimicrobial overuse, improving outcomes and resource utilization.
    • Post‑discharge outcomes and care‑transition studies assessing multidisciplinary follow‑up, home wound care delivery models, and readmission prevention for patients discharged after skin grafting for ulcers or cellulitis: these cohort or implementation trials track wound healing rates, outpatient visit frequency, emergency visits, and 30‑ to 90‑day readmission among older adults and medically complex patients. Such research focuses on the recovery and rehabilitation phase and is relevant to hospitals and payers interested in reducing avoidable readmissions, ensuring continuity of care, and evaluating cost‑effectiveness of post‑acute services like home nursing and telehealth wound monitoring.

    Related Codes

    570-SKIN-DEBRIDEMENT-WITH-MCC

    Skin Debridement with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    571-SKIN-DEBRIDEMENT-WITH-CC

    Skin Debridement with CC: Inpatient Reimbursement Overview

    572-SKIN-DEBRIDEMENT-WITHOUT-CC-MCC

    Skin Debridement without CC/MCC: Inpatient Reimbursement Overview

    573-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    574-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    576-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    577-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft Except for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    578-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    579-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-MCC

    Other Skin, Subcutaneous Tissue and Breast Procedures with MCC: Inpatient Reimbursement Overview

    580-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-CC

    Other Skin, Subcutaneous Tissue and Breast Procedures with CC: Inpatient Reimbursement Overview

    Showing 1–10 of 31

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.